Key result
Postoperative surgery substantially shortens rADAMTS13 half-life to ~43 hours in cTTP, prompting intensified dosing.
Case Report (n=1)
No
Perioperative management of cTTP with an intensified, adapted dosing regimen of recombinant ADAMTS13 is safe and effective, compensating for the reduced half-life observed after major surgery.
Answers are grounded in this paper and cite their sources.
Recombinant ADAMTS13 enabled uncomplicated hip arthroplasty in cTTP; leaves open optimal perioperative dosing due to accelerated consumption.
A 41 year old female with congenital thrombotic thrombocytopenic purpura (cTTP) underwent a total hip arthroplasty under prophylaxis with recombinant ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin motifs 13). The procedure was performed without complications 12 h after the last injection. Postoperative ADAMTS13 activity levels showed a more rapid decrease in activity and in the individual apparent half-life due to increased consumption of the recombinant protease that could safely be managed by an intensified dosing regimen.
No takes yet. Share an insight, caveat, or question.
Weise et al. (2025) conducted a case report in Congenital thrombotic thrombocytopenic purpura (cTTP) (n=1). Recombinant ADAMTS13 was evaluated on Apparent half-life of rADAMTS13. In a patient with cTTP undergoing total hip arthroplasty, the apparent half-life of recombinant ADAMTS13 was substantially reduced to 43.3 hours in the immediate postoperative period, requiring intensified dosing.
Synapse has enriched 10 related papers. Consider them for comparative context: